In vitro activity of meropenem-ANT3310 and comparators against carbapenem resistant Acinetobacter clinical isolates: implications for low and middle-income countries (LMIC)
In vitro activity of meropenem-ANT3310 and comparators against carbapenem resistant Acinetobacter clinical isolates: implications for low and middle-income countries (LMIC)
